These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
129 related items for PubMed ID: 10470206
21. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study. Sözen S, Eskicorapci S, Küpeli B, Irkilata L, Altinel M, Ozer G, Uygur C, Alkibay T, Ozen H. Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190 [Abstract] [Full Text] [Related]
27. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG. Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5361-7. PubMed ID: 17875764 [Abstract] [Full Text] [Related]
28. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer. Nanri M, Nanri K, Fujiyama C, Tokuda Y, Nakamura K, Uozumi J. Int J Urol; 2007 Jun 15; 14(6):505-9. PubMed ID: 17593094 [Abstract] [Full Text] [Related]
29. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. Soergel TM, Koch MO, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH. J Urol; 2001 Dec 15; 166(6):2198-201. PubMed ID: 11696735 [Abstract] [Full Text] [Related]
31. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer. Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ. Urology; 2004 Mar 15; 63(3):492-8. PubMed ID: 15028444 [Abstract] [Full Text] [Related]
32. [PSA and follow-up after treatment of prostate cancer]. Benchikh El Fegoun A, Villers A, Moreau JL, Richaud P, Rebillard X, Beuzeboc P. Prog Urol; 2008 Mar 15; 18(3):137-44. PubMed ID: 18472065 [Abstract] [Full Text] [Related]
35. Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Berger AP, Spranger R, Kofler K, Steiner H, Bartsch G, Horninger W. Prostate; 2003 Oct 01; 57(2):93-8. PubMed ID: 12949932 [Abstract] [Full Text] [Related]
36. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. de Vries SH, Raaijmakers R, Blijenberg BG, Mikolajczyk SD, Rittenhouse HG, Schröder FH. Urology; 2005 May 01; 65(5):926-30. PubMed ID: 15882725 [Abstract] [Full Text] [Related]
37. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ. Urology; 2006 Feb 01; 67(2):343-8. PubMed ID: 16442594 [Abstract] [Full Text] [Related]
38. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. Noguchi M, Stamey TA, Neal JE, Yemoto CE. J Urol; 2000 Jun 01; 163(6):1751-5. PubMed ID: 10799175 [Abstract] [Full Text] [Related]